National Human Genome Research Institute; Notice of Meeting, 49873-49874 [2022-17304]

Download as PDF Federal Register / Vol. 87, No. 155 / Friday, August 12, 2022 / Notices jspears on DSK121TN23PROD with NOTICES Mandatory Disclosure Requirements As required by 2 CFR part 200 of the Uniform Guidance, and the HHS implementing regulations at 45 CFR part 75, the IHS must require an NFE or an applicant for a Federal award to disclose, in a timely manner, in writing to the IHS or pass-through entity all violations of Federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the Federal award. All applicants and awardees must disclose in writing, in a timely manner, to the IHS and to the HHS Office of Inspector General all information related to violations of Federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the Federal award. 45 CFR 75.113. Disclosures must be sent in writing to: U.S. Department of Health and Human Services, Indian Health Service, Division of Grants Management, ATTN: Marsha Brookins, Director, 5600 Fishers Lane, Mail Stop: 09E70, Rockville, MD 20857, (Include ‘‘Mandatory Grant Disclosures’’ in subject line), Office: (301) 443–4750, Fax: (301) 594–0899, Email: DGM@ ihs.gov AND U.S. Department of Health and Human Services, Office of Inspector General, ATTN: Mandatory Grant Disclosures, Intake Coordinator, 330 Independence Avenue SW, Cohen Building, Room 5527, Washington, DC 20201, URL: https://oig.hhs.gov/fraud/reportfraud/, (Include ‘‘Mandatory Grant Disclosures’’ in subject line), Fax: (202) 205–0604 (Include ‘‘Mandatory Grant Disclosures’’ in subject line) or Email: MandatoryGranteeDisclosures@ oig.hhs.gov Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371 Remedies for noncompliance, including suspension or debarment (see 2 CFR part 180 and 2 CFR part 376). VII. Agency Contacts 1. Questions on the programmatic issues may be directed to: Ms. Carmen Licavoli Hardin, Acting Director, Indian Health Service, Division of Diabetes Treatment and Prevention, 5600 Fishers Lane, Mail Stop: 08N34A&B, Rockville, MD 20897, Phone: 1–844–IHS–DDTP (1–844–447–3387), Fax: 301–594–6213, Email: diabetesprogram@ihs.gov. 2. Questions on grants management and fiscal matters may be directed to: Donald Gooding, Senior Grants Management Specialist, Indian Health Service, Division of Grants VerDate Sep<11>2014 17:38 Aug 11, 2022 Jkt 256001 Management, 5600 Fishers Lane, Mail Stop: 09E70, Rockville, MD 20857, Phone: 301–443–2298, Email: Donald.Gooding@ihs.gov. 3. Questions on systems matters may be directed to: Paul Gettys, Deputy Director, Indian Health Service, Division of Grants Management, 5600 Fishers Lane, Mail Stop: 09E70, Rockville, MD 20857, Phone: (301) 443– 2114; or the DGM main line (301) 443– 5204, E-Mail: Paul.Gettys@ihs.gov. VIII. Other Information The Public Health Service strongly encourages all grant, cooperative agreement, and contract awardees to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103– 227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of the facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the HHS mission to protect and advance the physical and mental health of the American people. Elizabeth A. Fowler, Acting Director, Indian Health Service. [FR Doc. 2022–17403 Filed 8–11–22; 8:45 am] BILLING CODE 4165–16–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Human Genome Research. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend as well as those who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from https://www.genome.gov/ about-nhgri/Institute-Advisors/ National-Advisory-Council-for-HumanGenome-Research. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 49873 confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Human Genome Research. Date: September 19–20, 2022. Closed: September 19, 2022, 9:00 a.m. to 9:30 a.m. Agenda: To review and evaluate grant applications. Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892. Open: September 19, 2022, 10:00 a.m. to 6:30 p.m. Agenda: Report of Institute Director and Institute Staff. Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892. Closed: September 20, 2022, 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892. Contact Person: Rudy O. Pozzatti, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892, (301) 402–0838, pozzattr@ mail.nih.gov. Any interested person may file written comments with the committee within 15 days after the meeting by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Additional Health and Safety Guidance: Before attending a meeting at an NIH facility, it is important that visitors review the NIH COVID–19 Safety Plan at https:// ors.od.nih.gov/sr/dohs/safety/NIH-covid-19safety-plan/Pages/default.aspx and the NIH testing and assessment web page at https:// ors.od.nih.gov/sr/dohs/safety/NIH-covid-19safety-plan/COVID-assessment-testing/Pages/ visitor-testing-requirement.aspx for information about requirements and procedures for entering NIH facilities, especially when COVID–19 community E:\FR\FM\12AUN1.SGM 12AUN1 49874 Federal Register / Vol. 87, No. 155 / Friday, August 12, 2022 / Notices levels are medium or high. In addition, the Safer Federal Workforce website has FAQs for visitors at https:// www.saferfederalworkforce.gov/faq/visitors/. Please note that if an individual has a COVID–19 diagnosis within 10 days of the meeting, that person must attend virtually. (For more information please read NIH’s Requirements for Persons after Exposure at https://ors.od.nih.gov/sr/dohs/safety/NIHcovid-19-safety-plan/COVID-assessmenttesting/Pages/persons-after-exposure.aspx and What Happens When Someone Tests Positive at https://ors.od.nih.gov/sr/dohs/ safety/NIH-covid-19-safety-plan/COVIDassessment-testing/Pages/test-positive.aspx.) Anyone from the public can attend the open portion of the meeting virtually via the NIH Videocasting website (https:// videocast.nih.gov). Please continue checking these websites, in addition to the committee website listed below, for the most up to date guidance as the meeting date approaches. Information is also available on the Institute’s/Center’s home page: https:// www.genome.gov/council, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: August 8, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17304 Filed 8–11–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting jspears on DSK121TN23PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Aging Bone/ Muscle. Date: October 6, 2022. Time: 12:30 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Aging, Gateway VerDate Sep<11>2014 17:38 Aug 11, 2022 Jkt 256001 Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Nijaguna Prasad, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, 7201 Wisconsin Avenue, Gateway Bldg., Suite 2W200, Bethesda, MD 20892, (301) 496– 9667, prasadnb@nia.nih.gov. Information is also available on the Institute’s/Center’s home page: www.nia.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: August 8, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17307 Filed 8–11–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel, Hearing loss and Alzheimer’s. Date: September 13, 2022. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Anita H. Undale, Ph.D., MD, Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 827–7428, anita.undale@ nih.gov. Information is also available on the Institute’s/Center’s home page: www.nia.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. PO 00000 Frm 00076 Fmt 4703 Sfmt 9990 (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: August 8, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17303 Filed 8–11–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; SenescenceCell Death Decisions in Aging. Date: November 7, 2022. Time: 11:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Joshua Jin-Hyouk Park, Scientific Review Officer, Scientific Review Branch, NIA (National Institute on Aging), GWY BG RM 2W200, 7201 Wisconsin Ave, Bethesda, MD 20892, (301) 496–6208, joshua.park4@nih.gov. Information is also available on the Institute’s/Center’s home page: www.nia.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: August 8, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17305 Filed 8–11–22; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\12AUN1.SGM 12AUN1

Agencies

[Federal Register Volume 87, Number 155 (Friday, August 12, 2022)]
[Notices]
[Pages 49873-49874]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17304]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council for Human Genome Research.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
as well as those who need special assistance, such as sign language 
interpretation or other reasonable accommodations, should notify the 
Contact Person listed below in advance of the meeting. The meeting will 
be videocast and can be accessed from https://www.genome.gov/about-nhgri/Institute-Advisors/National-Advisory-Council-for-Human-Genome-Research.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Council for Human Genome 
Research.
    Date: September 19-20, 2022.
    Closed: September 19, 2022, 9:00 a.m. to 9:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: National Human Genome Research Institute, National 
Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, 
MD 20892.
    Open: September 19, 2022, 10:00 a.m. to 6:30 p.m.
    Agenda: Report of Institute Director and Institute Staff.
    Place: National Human Genome Research Institute, National 
Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, 
MD 20892.
    Closed: September 20, 2022, 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Human Genome Research Institute, National 
Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, 
MD 20892.
    Contact Person: Rudy O. Pozzatti, Ph.D., Scientific Review 
Officer, Scientific Review Branch, National Human Genome Research 
Institute, National Institutes of Health, 6700B Rockledge Drive, 
Suite 1100, Bethesda, MD 20892, (301) 402-0838, 
[email protected].

    Any interested person may file written comments with the 
committee within 15 days after the meeting by forwarding the 
statement to the Contact Person listed on this notice. The statement 
should include the name, address, telephone number and when 
applicable, the business or professional affiliation of the 
interested person.
    In the interest of security, NIH has procedures at https://www.nih.gov/about-nih/visitor-information/campus-access-security for 
entrance into on-campus and off-campus facilities. All visitor 
vehicles, including taxicabs, hotel, and airport shuttles will be 
inspected before being allowed on campus. Visitors attending a 
meeting on campus or at an off-campus federal facility will be asked 
to show one form of identification (for example, a government-issued 
photo ID, driver's license, or passport) and to state the purpose of 
their visit.
    Additional Health and Safety Guidance: Before attending a 
meeting at an NIH facility, it is important that visitors review the 
NIH COVID-19 Safety Plan at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/Pages/default.aspx and the NIH testing and 
assessment web page at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/visitor-testing-requirement.aspx for information about requirements and procedures 
for entering NIH facilities, especially when COVID-19 community

[[Page 49874]]

levels are medium or high. In addition, the Safer Federal Workforce 
website has FAQs for visitors at https://www.saferfederalworkforce.gov/faq/visitors/. Please note that if an 
individual has a COVID-19 diagnosis within 10 days of the meeting, 
that person must attend virtually. (For more information please read 
NIH's Requirements for Persons after Exposure at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/persons-after-exposure.aspx and What 
Happens When Someone Tests Positive at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/test-positive.aspx.) Anyone from the public can attend the open 
portion of the meeting virtually via the NIH Videocasting website 
(https://videocast.nih.gov). Please continue checking these websites, 
in addition to the committee website listed below, for the most up 
to date guidance as the meeting date approaches.
    Information is also available on the Institute's/Center's home 
page: https://www.genome.gov/council, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: August 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-17304 Filed 8-11-22; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.